VANCOUVER, British Columbia, June 14, 2019
Lungpacer Medical, Inc., announced today the enrollment of the first subject in the RESCUE 3 IDE clinical study of its proprietary phrenic-nerve pacing system. The RESCUE 3 study will be conducted in the US, Europe and other Tier 1 countries and will evaluate the safety and effectiveness of Lungpacer’s LIVE Catheter and pacing system, to improve inspiratory muscle strength and weaning success for subjects who have failed two or more weaning attempts and required prolonged mechanical ventilation of ≥96 hours. The subject was enrolled at University of Texas Southwestern Medical Center in Dallas, Texas.
More information at www.Rescue3Study.com
